Brain Tumor Susceptibility: the Role of Genetic Factors and Uses of Mouse Models to Unravel Risk

par Reilly, Karlyne M.
Publié 2008

Neurofibromatosis and lessons for the war on cancer

par Reilly, Karlyne M
Publié 2009

Extending the Convergence of Canonical WNT Signaling and Classic Cancer Pathways for Treatment of Malignant Peripheral Nerve Sheath Tumors

par Reilly, Karlyne M.
Publié dans Cancer Discov (2013)

Protocol 1: Controlling genetic background in crosses of mouse models of cancer

par Reilly, Karlyne M.
Publié dans Cold Spring Harb Protoc (2016)

The effects of genetic background of mouse models of cancer: friend or foe?

par Reilly, Karlyne M.
Publié dans Cold Spring Harb Protoc (2016)

Protocol 2: Using the Collaborative Cross to study the role of genetic diversity in cancer-related phenotypes

par Reilly, Karlyne M.
Publié dans Cold Spring Harb Protoc (2016)

The role of the immune system in neurofibromatosis type 1-associated nervous system tumors

par Karmakar, Souvik, Reilly, Karlyne M
Publié dans CNS Oncol (2017)

Nature and Nurture: It Takes a [Dysfunctional] Village to Raise a Tumor

par Reilly, Karlyne M., Van Dyke, Terry
Publié 2008

Bioluminescent Approaches for Measuring Tumor Growth in a Mouse Model of Neurofibromatosis

par HAWES, JESSICA J., REILLY, KARLYNE M.
Publié dans Toxicol Pathol (2010)

Novel Dual-Reporter Preclinical Screen for Anti-Astrocytoma Agents Identifies Cytostatic and Cytotoxic Compounds

par Hawes, Jessica J., Nerva, John D., Reilly, Karlyne M.
Publié 2008

Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies

par Hawes, Jessica J., Tuskan, Robert G., Reilly, Karlyne M.
Publié dans Neurogenetics (2007)

Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency

par Pemov, Alexander, Park, Caroline, Reilly, Karlyne M, Stewart, Douglas R
Publié 2010

Genetically Engineered Mouse Models in Cancer Research

par Walrath, Jessica C., Hawes, Jessica J., Van Dyke, Terry, Reilly, Karlyne M.
Publié 2010

Developing therapies for rare tumors: opportunities, challenges and progress

par Bradford, Diana, Reilly, Karlyne M, Widemann, Brigitte C, Sandler, Abby, Kummar, Shivaani
Publié dans Expert Opin Orphan Drugs (2015)

Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5

par Amlin-Van Schaick, Jessica C., Kim, Sungjin, Broman, Karl W., Reilly, Karlyne M.
Publié 2011

Chr 19(A/J) modifies tumor resistance in a sex and parent-of-origin specific manner

par Walrath, Jessica C., Fox, Kristi, Truffer, Erika, Alvord, W. Gregory, Quiñones, Octavio A., Reilly, Karlyne M.
Publié 2009

Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies

par Kim, AeRang, Stewart, Douglas R., Reilly, Karlyne M., Viskochil, David, Miettinen, Markku M., Widemann, Brigitte C.
Publié dans Sarcoma (2017)

Re-thinking Brain Tumors: The Fourth Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop

par Reilly, Karlyne M., Rubin, Joshua B., Gilbertson, Richard J., Garbow, Joel R., Roussel, Martine F., Gutmann, David H.
Publié 2008

Isobutylhydroxyamides from the Pericarp of Nepalese Zanthoxylum armatum Inhibit NF1-defective Tumor Cell Line Growth

par Devkota, Krishna P., Wilson, Jennifer, Henrich, Curtis J., McMahon, James B., Reilly, Karlyne M., Beutler, John A.
Publié 2012

Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors

par Hatano, Manabu, Kuwashima, Naruo, Tatsumi, Tomohide, Dusak, Jill E, Nishimura, Fumihiko, Reilly, Karlyne M, Storkus, Walter J, Okada, Hideho
Publié 2004